Physiomics wins major new pharma client

Technology-based cancer treatment solutions provider Physiomics announced on Friday that it has been awarded a contract by an unnamed new major pharmaceutical client.

The AIM-traded company said the project, which was expected to be completed during its current financial year, involves the use of its ‘Virtual Tumour’ technology in a pre-clinical setting, with a value of approximately £35k.

Physiomics said its Virtual Tumour is a sophisticated computer model that simulates tumour cell division and predicts the effect of different anti-cancer regimes to support pre-clinical and clinical oncology development programs.

It added that Virtual Tumour helps customers to balance efficacy and toxicity, and to prioritise the most effective drug combinations while reducing time and cost.

“We are delighted to be working with a significant new client,” said Physiomics CEO Jim Millen.

“If this initial project is successful, we would hope to develop a longer-term relationship.”